Institutional investors must be pleased after a 8.9% gain last week that adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) one-year returns [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
50% of the business is held by the top 21 shareholders Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business A look at the shareholders of CRISPR Therapeutics AG ( NASDAQ:CRSP ) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 67% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). And as as result, institutional investors reaped the most rewards after the company's stock price gained 8.9% last week. One-year return to shareholders is currently 4.1% and last week's gain was the icing on the cake. Let's take a closer look to see what the different types of shareholders can tell us about CRISPR Therapeutics. View our latest analysis for CRISPR Therapeutics What Does The Institutional Ownership Tell Us About CRISPR Therapeutics? Many institutions measure their performance against an index that app
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- FDA will not meet ahead of bluebird bio's sickle cell disease gene therapy PDUFA date [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- CRISPR Gene Editing Market Size Projected to Surpass $2 Billion by 2024 Amid Increasing Demand for Genetic Treatments - Long-term Forecast to 2028 and 2033 [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Truist Financial Co. from $120.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 8/12/24 - Form 4
- 8/5/24 - Form S-3ASR
- 8/5/24 - Form S-8
- CRSP's page on the SEC website